Respiratory syncytial virus F protein
| Fusion glycoprotein F0 | |||||||
|---|---|---|---|---|---|---|---|
| Identifiers | |||||||
| Organism | |||||||
| Symbol | F | ||||||
| Entrez | 1489825 | ||||||
| RefSeq (mRNA) | NC_001781.1 | ||||||
| RefSeq (Prot) | NP_056863.1 | ||||||
| UniProt | O36634 | ||||||
| Other data | |||||||
| Chromosome | Genomic: 0.01 - 0.01 Mb | ||||||
| |||||||
Fusion glycoprotein F0 of the human respiratory syncytial virus (RSV) is a critical fusion glycoprotein that facilitates entry of the virus into host cells by mediating the fusion of the viral and cellular membranes. This class I fusion protein is synthesized as an inactive precursor (F0), which undergoes cleavage to form two disulfide linked subunits, F1 and F2, that are essential for its fusion activity.[1] The RSV F protein exists in two conformations: a metastable prefusion form and a stable postfusion form, with the prefusion form being a major target for neutralizing antibodies due to its role in viral entry. The structural transitions of the F protein during the fusion process are crucial for its function, making it a significant focus in the development of vaccines and antiviral therapies against RSV infections.[2]
See also
- Nirsevimab, an approved medication, whole human monoclonal antibody against F protein
References
- ↑ McDonald TP, Sugrue RJ (2007). "The use of two-dimensional SDS-PAGE to analyze the glycan heterogeneity of the respiratory syncytial virus fusion protein". Glycovirology Protocols. Methods in Molecular Biology. Vol. 379. Clifton, N.J.: Humana Press. pp. 97–108. doi:10.1007/978-1-59745-393-6_7. ISBN 978-1-58829-590-3. PMID 17502673.
- ↑ Li X, Yu X, Du Z, Zhang L, Wang Y, Wu Y, Lin Y, He Y (October 2024). "Prevention of respiratory syncytial virus from 1991 to 2024: a systematic review and bibliometrics analysis". Translational Pediatrics. 13 (10): 1858–1869. doi:10.21037/tp-24-271. PMC 11543136. PMID 39524391.